Clinical significance of ADAMTS-13/vWF axis in pregnant women at different trimesters of gestation

Introduction. The pandemic of a novel coronavirus infection has demonstrated the importance of assessing the ADAMTS-13/vWF axis in patients with COVID-19, because a decline in this ratio mirrors disease severity. However very few data in the global literature on crosstalk and ADAMTS-13/vWF levels in pregnant women remaining very contradictory are available. Taking into consideration an impact of the ADAMTS-13/vWF axis on prevalence of thrombosis and disorders in the hemostasis system, investigation of this issue is highly demanded.Aim: to assess the functioning of the ADAMTS-13/vWF axis during physiological pregnancy.Materials and Methods. A controlled non-randomized study was conducted: main group included 44 women with physiologically occurring pregnancies at I, II and III trimesters; the control group consisted of 45 healthy non-pregnant women. The plasma level of ADAMTS-13 inhibitor (ADAMTS-13:i), ADAMTS-13 antigen (ADAMTS-13:Ag), vWF antigen (vWF:Ag), and ADAMTS-13 activity (ADAMTS-13:Ac) as well as relevant ratio (ADAMTS-13:Ac/vWF:Ag) were measured.Results. It was shown that in parallel with increasing gestational age, significant changes occurred in the ADAMTS-13:Ac/vWF:Ag ratio. In main group, patients at II trimester were found to have level of ADAMTS-13:Ac/vWF:Ag 0.359 ± 0.121, in III trimester –0.253 ± 0.741, which significantly differed (p < 0.01) compared to control group with non-pregnant women (1,134 ± 0,308).Conclusion. Our study provides new insights into the functioning of the ADAMTS-13:/vWF axis in women with physiologically occurring pregnancy at I, II and III trimesters. Decline in ADAMTS-13:Ac was demonstrated along with increasing vWF:Ag level observed in parallel with increasing gestational age. Apparently, the progressive decrease of ADAMTS-13 concentration during pregnancy is associated with its increased consumption due to high vWF level. However, due to the small single-center patient cohort, further studies with larger-scale studies are needed.

[1]  G. Tiscia,et al.  Obstetric outcomes in pregnant COVID-19 women: the imbalance of von Willebrand factor and ADAMTS13 axis , 2022, BMC Pregnancy and Childbirth.

[2]  É. Azoulay,et al.  Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID‐19 patients , 2021, Journal of Thrombosis and Haemostasis.

[3]  G. Lippi,et al.  Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis , 2021, Seminars in Thrombosis and Hemostasis.

[4]  J. Li,et al.  Association of placenta‐derived extracellular vesicles with pre‐eclampsia and associated hypercoagulability: a clinical observational study , 2020, BJOG : an international journal of obstetrics and gynaecology.

[5]  M. Ramadan,et al.  HELLP Syndrome, Thrombotic Thrombocytopenic Purpura or Both: Appraising the Complex Association and Proposing a Stepwise Practical Plan for Differential Diagnosis , 2017, Journal of hematology.

[6]  O. Christophe,et al.  von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. , 2015, Blood.

[7]  B. Konkle,et al.  Complex Changes in von Willebrand Factor-Associated Parameters Are Acquired during Uncomplicated Pregnancy , 2014, PloS one.

[8]  S. D. De Meyer,et al.  Unwinding the von Willebrand factor strings puzzle. , 2013, Blood.

[9]  T. Walz,et al.  Sequence and structure relationships within von Willebrand factor. , 2012, Blood.

[10]  Z. Berneman,et al.  Laboratory Diagnosis of von Willebrand Disease Type 1/2E (2A Subtype IIE), Type 1 Vicenza and Mild Type 1 Caused by Mutations in the D3, D4, B1–B3 and C1–C2 Domains of the von Willebrand Factor Gene , 2009, Acta Haematologica.

[11]  A. Franx,et al.  Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome , 2006, Journal of thrombosis and haemostasis : JTH.